Regeneron Pharmaceuticals, Inc. (RGO.F)
| Previous Close | 936.60 |
| Open | 944.80 |
| Bid | 944.00 x 2800 |
| Ask | 950.00 x 2800 |
| Day's Range | 944.80 - 944.80 |
| 52 Week Range | 628.00 - 1,007.50 |
| Volume | |
| Avg. Volume | 7 |
| Market Cap | 105.906B |
| Beta (5Y Monthly) | 0.13 |
| PE Ratio (TTM) | 30.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
- Reuters
EU approves Sanofi's Dupixent for 'smoker's lungs'
The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a recommendation by the European Medicines Agency (EMA) at the end of May. The debilitating disease is also known as 'smoker's lungs' because in western countries it primarily affects cigarette smokers.
- GuruFocus.com
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 17,882 shares of Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
